The number of new graduates hired for sales rep roles increased in FY2025 after declining for five consecutive years, a…
HOME > COMMENTARY
COMMENTARY
- COMMENTARY／Combination Drugs Becoming a "Boom"
June 1, 2009
- COMMENTARY／Clearer Criteria Needed for Patent Period Restoration
May 4, 2009
- COMMENTARY／Why Does the Use of Generics Not Increase?
April 27, 2009
- EMTs Allowed to Administer Epipen
April 27, 2009
- COMMENTARY／Medway Data Falsification to Make Blood Product Self-Sufficiency Difficult
April 20, 2009
- The First Round Results of GE Amlodipine (2)- Making No Surprise Moves Leads to Success -
April 6, 2009
- COMMENTARY／Worst Scenario Coming True due to Heated Competition among Wholesalers
March 23, 2009
- Unexpected Demand for ActHIB Causes Shortage of Supply
March 16, 2009
- COMMENTARY／Aggressive Overseas Investments Affect Business of Top-4 Pharmas
February 23, 2009
- COMMENTARY／National Consensus Needed to Balance Soaring Costs of New Drugs against Their Benefits
February 16, 2009
- Majority of People Have Misconceptions about Antibacterials: Pfizer Survey
February 9, 2009
- Patent Expiration of Blockbusters and New Breakthrough Candidates from Japanese Pharmaceutical Companies
February 9, 2009
- Paltac/Alfresa Merger Plan Canceled, but Distribution Reform Remains to Be Done
February 2, 2009
- COMMENTARY／Industry Should Guarantee Development of Innovative Drugs and Use of More Generics
January 19, 2009
- COMMENTARY／Aiming at Further Growth beyond Global Recession
January 12, 2009
- COMMENTARY／Rule to Restrict Participation in CDFS Committee Deliberations Needs Continued Validation
January 5, 2009
- COMMENTARY／Will Economic Incentives for Med. Institutions Be Effective to Promote Use of Generics?
December 22, 2008
- Commentary／Issue of Online Sales of OTC Drugs at Standstill
December 15, 2008
- COMMENTARY／Toyota, NEC Start Direct Inspection, Payment of Medical Bills
December 8, 2008
- COMMENTARY／Will VITAL KSK Become Core of Alliance of Regional Wholesalers?
December 8, 2008
ページ
The traditional HR Business Partner (HRBP) model, once the gold standard for HR delivery, is undergoing a significant transformation. Many organizations, particularly in industries like pharmaceuticals, are moving towards a more agile resource model, aiming to streamline HR operations and…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…